Servier Acquires Muscular Dystrophy Business from Edgewise Therapeutics

Editor’s Take: With this transaction, Edgewise Therapeutics transitions to a cardiovascular-focused company and Servier becomes a new player in rare neurology.

Edgewise Therapeutics Inc., a clinical-stage biopharmaceutical company, has completed its previously announced sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.

The transaction aims to strengthen Edgewise’s balance sheet, provide enhanced financial flexibility and sharpen the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. With this transaction, Edgewise transitions to a cardiovascular-focused company.

Under the terms of the agreement, Servier acquired all rights to sevasemten, including related intellectual property, know-how, key agreements, regulatory filings, and clinical data required to operate the muscular dystrophy business. The core Edgewise employee group primarily supporting the muscular dystrophy business received offers to transition to Servier to ensure continuity of development and future commercial execution.

Kevin Koch, Ph.D., President and CEO of Edgewise Therapeutics, said, “We’re confident Servier’s global scale, deep expertise in rare diseases, and commitment to patients will help fully realize sevasemten’s potential for individuals living with Becker and Duchenne muscular dystrophy.”

Olivier Laureau, President of Servier, added, “With the successful closing of this acquisition, we are pleased to welcome a highly experienced team and a strong ambition in Becker and Duchenne muscular dystrophy to Servier. This is a strategic milestone in achieving Servier 2030 to become a new player in rare neurology and to serve patients living with devastating rare diseases.”

This acquisition follows Servier’s acquisition of Day One Biopharmaceuticals earlier this year.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.